Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
In its Q3 2026 13F filing, Paradigm Biocapital Advisors LP disclosed 29 equity positions with a combined reported value of $5.03B. The filing implies a focused portfolio: its ten largest positions account for 78.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M). By sector, the heaviest allocations are Health Care 99.7%, Other 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+18.5pp) and away from Industrials (-0.8pp), Other (-17.7pp).
Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 63% of names.
The largest new positions opened in Q3 2026 were BBIO ($154.49M), GPCR ($40.63M), MANE ($37.59M).
Of the 6 positions fully exited versus the prior quarter, the largest were NUVL ($731.67M), APGE ($209.23M), ALNY ($144.49M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 29 positions worth $5.03B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
29 positions · $5.03B reported value (Q3 2026)
Top 10 holdings = 78.6% of reported value
Largest position: RVMD (REVOLUTION MEDICINES INC) at 25.4%
Average position size: $173.41M
Sector Tilt
Health Care 99.7%
(classified holdings cover 100% of value)
Quarterly Activity
Q3 2026: 7 new, 13 added, 6 reduced, 6 exited
3 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund is actively increasing exposure to high-growth biotech/healthcare names (e.g., INSM, VRDN, MBX) while trimming some established positions (RVMD, BLTE, TARS), suggesting a bullish stance on innovative therapeutics but selective profit-taking.
2. Key moves:
- Added: GMAB (+3.28% wt), EWTX (+0.93% wt), SYRE (+1.51% wt), INSM (+3.47% wt), VRDN (+2.20% wt), MBX (+1.81% wt), ORKA (+0.31% wt).
- Reduced: RVMD (-2.92% wt), BLTE (-0.30% wt), TARS (-0.33% wt).
3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with aggressive growth bias (e.g., INSM +103% shares) and moderate risk appetite (top-10 holds 88.63% of $5B).
4. Per-holding one-liner:
- RVMD: Revolution Medicines (oncology)
- GMAB: Genmab A/S (antibody therapeutics)
- EWTX: Edgewise Therapeutics (fibrosis)
- SYRE: Spyre Therapeutics (inflammation)
- INSM: Insmed Inc (antibiotics)
- VRDN: Viridian Therapeutics (thyroid disease)
- MBX: MBX Biosciences (unverified)
- ORKA: Oruka Therapeutics (unverified)
- BLTE: Belite Bio (eye diseases)
- TARS: Tarsus Pharmaceuticals (ophthalmology)
5. Style summary: Aggressive biotech fund doubling down on high-growth clinical-stage names while trimming select large caps.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:02
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 32% of its Top-10 each quarter and
backtests at F1 71% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return-10.82%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+6.19%vs benchmark
Barra annualised vol55.8%Model estimate
Realised vol48.7%Annualised in window
Weighted beta1.01Raw exposure
Factor / specific risk34% / 66%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-10.82%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+6.19%
Portfolio − benchmark
Arithmetic return sum
-9.92%
Difference vs compounded is the cross term
Weighted raw beta
1.01
Weighted holding betas
Realised volatility (annualised)
48.66%
Daily returns in window
Barra model volatility (annualised)
55.75%
Factor + specific
Factor share of variance
33.7%
Barra factors
Specific share of variance
66.3%
Stock residuals
Reported value
$1.95B
13F long US equity
2. Return attribution
The -9.92% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+3.68%
37.1%
Momentum & Growth
3
-12.03%
-121.2%
Volatility & Tail Risk
7
+5.41%
54.5%
Industry
12
+6.98%
70.4%
Specific
1
-13.97%
-140.8%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Residual Volatility
Style
+2.46
+3.29%
+8.11%
81.8%
Health Care
Industry
+1.00
+6.98%
+6.98%
70.4%
Kurtosis
Style
+0.44
+7.51%
+3.30%
33.2%
Size
Style
-0.82
-1.95%
+1.60%
16.1%
Turnover
Style
-0.26
-4.80%
+1.26%
12.7%
Short-term Reversal
Style
+0.96
+0.87%
+0.84%
8.5%
Beta
Style
+0.15
+4.44%
+0.65%
6.6%
Mid Cap
Style
-0.33
-1.94%
+0.64%
6.5%
Leverage (Downside Vol)
Style
-0.31
-1.71%
+0.53%
5.3%
Non-linear Size
Style
+0.52
+1.01%
+0.53%
5.3%
Amihud Illiquidity
Style
+0.67
-0.45%
-0.30%
-3.0%
Growth
Style
-0.97
+1.75%
-1.69%
-17.0%
Skewness
Style
+0.69
-4.39%
-3.04%
-30.6%
Historical Volatility
Style
+0.29
-14.00%
-4.11%
-41.4%
Momentum
Style
+2.80
-4.00%
-11.18%
-112.7%
Specific
Specific
—
—
-13.97%
-140.8%
3. Risk attribution
Annualised volatility is 55.75%; factor risk explains 33.7% of variance and specific risk 66.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
66.3%
+36.99%
37.0%
Momentum
Style
+2.80
16.7%
+9.29%
9.3%
Health Care
Industry
+1.00
9.0%
+5.03%
5.0%
Residual Volatility
Style
+2.46
5.5%
+3.08%
3.1%
Short-term Reversal
Style
+0.96
1.8%
+1.00%
1.0%
Size
Style
-0.82
1.1%
+0.61%
0.6%
Beta
Style
+0.15
0.7%
+0.41%
0.4%
Kurtosis
Style
+0.44
0.7%
+0.36%
0.4%
Amihud Illiquidity
Style
+0.67
0.4%
+0.23%
0.2%
Leverage (Downside Vol)
Style
-0.31
0.3%
+0.16%
0.2%
Skewness
Style
+0.69
-0.2%
-0.12%
-0.1%
Historical Volatility
Style
+0.29
-0.4%
-0.22%
-0.2%
Non-linear Size
Style
+0.52
-0.6%
-0.33%
-0.3%
Growth
Style
-0.97
-1.3%
-0.72%
-0.7%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-0.82
+2.10
-2.92
Non-linear Size
+0.52
+1.68
-1.15
Mid Cap
-0.33
+0.13
-0.46
Beta
+0.15
+1.29
-1.15
Momentum
+2.79
+0.72
+2.08
Short-term Reversal
+0.96
-0.64
+1.60
Residual Volatility
+2.46
-0.40
+2.87
Historical Volatility
+0.29
+0.86
-0.57
Liquidity
-0.14
+0.11
-0.25
Amihud Illiquidity
+0.67
+1.16
-0.49
Turnover
-0.26
+0.21
-0.47
Growth
-0.97
+0.58
-1.55
Leverage (Downside Vol)
-0.31
+0.14
-0.45
Skewness
+0.69
+0.24
+0.45
Kurtosis
+0.44
+0.21
+0.22
Max Drawdown
+0.02
-0.08
+0.10
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.26%
-0.27%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Industrials
0.0%
11.1%
+0.00%
+4.36%
-2.39%
-0.48%
+0.48%
-0.48%
Health Care
100.0%
1.7%
-10.75%
+8.29%
+24.98%
-0.33%
-18.71%
-10.89%
Total
+23.98%
+15.51%
-34.55%
+4.95%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
RVMD
REVOLUTION MEDICINES INC
Health Care
65.36%
-18.70%
-12.22%
Reduce
INSM
INSMED INC
Health Care
15.75%
+7.66%
+1.21%
Add
TNGX
TANGO THERAPEUTICS INC
Health Care
8.89%
-3.13%
-0.28%
Add
BBIO
BRIDGEBIO PHARMA INC
Health Care
7.91%
+17.57%
+1.39%
New
GPCR
STRUCTURE THERAPEUTICS INC
Health Care
2.08%
-40.61%
-0.84%
New
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
BBIO
Health Care
7.91%
+17.57%
+1.39%
2
INSM
Health Care
15.75%
+7.66%
+1.21%
3
TNGX
Health Care
8.89%
-3.13%
-0.28%
4
GPCR
Health Care
2.08%
-40.61%
-0.84%
5
RVMD
Health Care
65.36%
-18.70%
-12.22%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -10.82%, versus -17.01% for the QQQ synthetic benchmark — an excess of +6.19%.
Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.11%, Health Care +6.98%, Kurtosis +3.30%; the largest drags came from Momentum -11.18%, Historical Volatility -4.11%, Skewness -3.04%. Specific (stock-level) return contributed -13.97%.
Risk attribution: Barra model volatility is 55.75% annualised; factor risk explains 34% of variance and specific risk 66%. The largest factor risk sources are Momentum 16.7%, Health Care 9.0%, Residual Volatility 5.5%.
Style tilt: size -0.82, momentum +2.79, volatility +0.29, liquidity -0.14; the weighted raw beta is 1.01. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.51% and interaction -34.55%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Paradigm Biocapital Advisors LP buy in 2026-Q3?
In its 2026-Q3 13F filing, Paradigm Biocapital Advisors LP reported 29 equity positions worth $5.03B in aggregate; its largest disclosed positions were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M).
How large is Paradigm Biocapital Advisors LP's portfolio?
Paradigm Biocapital Advisors LP reported $5.03B of long equity holdings across 29 positions as of 2026-Q3. Top-10 holdings account for 78.6% of reported value.
What is Paradigm Biocapital Advisors LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>